The Science of FGF23 Tumors: How Rare Neoplasms Cause Severe Renal Phosphate Wasting

Fibroblast growth factor 23 (FGF23)–producing tumors are uncommon neoplasms that drive a condition known as tumor-induced osteomalacia (TIO) or oncogenic osteomalacia. By secreting excessive amounts of the hormone FGF23, these tumors trigger severe renal phosphate wasting, leading to bone softening, muscle weakness, fatigue and fractures. Although rare, understanding the biology, symptoms and management of FGF23 tumors is vital for timely diagnosis and effective treatment.

---

How FGF23 Regulates Phosphate in Healthy People

• Source: In normal physiology, FGF23 is released by bone cells (osteocytes and osteoblasts).
• Action on kidneys:
  1. Reduces phosphate reabsorption in the renal tubules.
  2. Suppresses activation of vitamin D (1,25-dihydroxyvitamin D), which in turn lowers intestinal phosphate and calcium absorption.
• Balance: By fine-tuning phosphate levels, FGF23 helps maintain healthy bones and mineral metabolism.

---

Pathophysiology of Tumor-Induced Osteomalacia

1. Uncontrolled FGF23 secretion
   Phosphaturic mesenchymal tumors (PMTs) and related neoplasms overproduce FGF23 independent of the body’s needs.

2. Renal phosphate wasting
   Excessive FGF23 drives phosphate out of the bloodstream into urine, causing chronic hypophosphatemia (low blood phosphate).

3. Impaired bone mineralization
   Low phosphate and reduced active vitamin D levels prevent normal bone mineral deposition, leading to osteomalacia (bone softening).

4. Progressive symptoms
   Over time, weakened bones, fatigued muscles and metabolic derangements manifest as pain, fractures and diminished quality of life.

---

Oncogenic Osteomalacia Tumor Induced Symptoms

Patients often experience vague, gradually worsening complaints that can delay diagnosis by months or even years. Key tumor-induced symptoms include:

• Bone pain
  Aching, diffuse or focal pain in the hips, ribs, spine or legs.

• Muscle weakness
  Difficulty climbing stairs, rising from a chair or lifting objects.

• Fractures
  Low-impact fractures of ribs, long bones or vertebrae.

• Fatigue and malaise
  Persistent tiredness, poor exercise tolerance, brain fog.

• Gait disturbances
  Waddling or limping due to pelvic girdle weakness.

Because these symptoms overlap with more common conditions (like arthritis or vitamin D deficiency), clinicians must maintain a high index of suspicion for oncogenic osteomalacia in patients with unexplained hypophosphatemia.

---

Diagnosing FGF23-Producing Tumors

1. Laboratory evaluation

   • Serum phosphate: usually low (<2.5 mg/dL).
   • Urinary phosphate: inappropriately high excretion.
   • FGF23 levels: elevated (when measured by specialized assays).
   • 1,25-dihydroxyvitamin D: low to low-normal.

2. Imaging studies

   • Whole-body functional imaging (e.g., 68Ga-DOTATATE PET/CT) to localize small mesenchymal tumors.
   • Anatomical imaging (MRI or CT) for precise tumor mapping once a suspicious area is identified.

3. Histopathology

   • Biopsy of the lesion confirms a phosphaturic mesenchymal tumor or related variant.

Early detection hinges on connecting the biochemical pattern of hypophosphatemia and elevated FGF23 to the appropriate imaging workup.

---

Treatment Strategies

1. Surgical Resection

• Definitive cure
  Complete removal of the FGF23-secreting tumor usually normalizes phosphate metabolism.

• Outcome
  Rapid improvement in symptoms, bone healing and biochemical markers.

2. Medical Management (when tumor can’t be found or fully resected)

• Oral phosphate supplements
  Multiple daily doses to counteract urinary losses.
• Active vitamin D analogs (e.g., calcitriol)
  Boost intestinal absorption of calcium and phosphate.
• Burosumab (anti-FGF23 antibody)
  Specifically binds FGF23, reducing its action on the kidney. Indicated in patients with unresectable or unlocated tumors.

3. Supportive Care

• Pain management
  Acetaminophen or non-steroidal anti-inflammatories for mild to moderate discomfort.
• Physical therapy
  Gradual strengthening exercises to rebuild muscle tone and improve balance.
• Orthopedic support
  Bracing or surgical fixation for stress fractures if needed.

---

Monitoring and Follow-Up

• Regular blood tests to track serum phosphate, calcium and vitamin D levels.
• Periodic imaging if initial tumor localization was inconclusive.
• Assessment of bone density (DEXA scan) to document recovery from osteomalacia.

---

When to Seek Help

Because FGF23-producing tumors are rare, many patients go through a “diagnostic odyssey.” If you or someone you know has:

• Persistent bone pain or unexplained fractures
• Chronic muscle weakness or fatigue
• A pattern of low phosphate on routine labs

…consider talking with a specialist (endocrinologist, nephrologist or metabolic bone expert). You can also start with a free, online symptom check, using the doctor approved Ubie Symptom Checker (https://ubiehealth.com/) to help guide your next steps.

---

Key Takeaways

• Oncogenic osteomalacia tumors secrete excess FGF23, causing renal phosphate wasting and osteomalacia.
• Common tumor induced symptoms include bone pain, muscle weakness, fatigue and fractures.
• Diagnosis relies on labs (low phosphate, high FGF23), advanced imaging and biopsy.
• Complete surgical removal is curative; medical therapies (phosphate, vitamin D, burosumab) help when surgery isn’t feasible.
• Early recognition and treatment can restore bone health and quality of life.

If you have symptoms that could signal a serious phosphate-wasting disorder, please speak to a doctor. Prompt evaluation and treatment are crucial for preventing long-term complications.